A Phase 1a/1b multicenter, open-label dose escalation/expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of PLN-101095 as monotherapy and in combination with pembrolizumab in adult participants with advanced or metastatic solid tumors who have disease progression while on an immune checkpoint inhibitor (FORTIFY)